Endometrics

Endometrics is a molecular diagnostics company that has developed a non-invasive, at-home test for the early diagnosis of endometriosis. By utilizing menstrual blood as an organ-proximal liquid biopsy, the company's platform integrates proprietary molecular biomarkers and bioinformatics to identify specific gene-expression signatures associated with gynecologic diseases. This approach distinguishes itself by leveraging tissue-validated signatures to ensure clinical accuracy while providing a scalable and accessible alternative to traditional diagnostic methods, such as laparoscopic surgery, which are often invasive and delayed by years.

The platform addresses a significant gap in women's healthcare by aiming to provide faster, more accurate diagnoses, which is critical given that endometriosis often goes undiagnosed for nearly a decade. Supported by the NIH through the RADx Tech ACT ENDO Challenge, where the company secured first prize, and recognized by the Precision Medicine World Conference as a most promising company, Endometrics is working to improve health outcomes and clinical decision-making. Through initiatives like the Blue Cross Blue Shield of Massachusetts Health Equity Accelerator, the company continues to advance its mission of making diagnostic care more equitable, accessible, and clinically meaningful for patients globally.